Mira Pharmaceuticals Inc (MIRA)

$1.25 +0.04 (3.31%)
Market Cap 20.47M
Revenue (ttm) 0.00
Net Income (ttm) -7.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 79,700
Avg Vol 1,491,476
Day's Range N/A - N/A
Shares Out 16.92M
Stochastic %K 22%
Beta 1.96
Analysts Strong Sell
Price Target $15.25

Company Profile

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic st...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 786-432-9792
Address:
1200 Brickell Avenue, Suite 1950 #1183, Miami, United States
Bulltrader988
Bulltrader988 Jun. 15 at 7:26 PM
$MIRA starts tomorrow 👀👀
0 · Reply
Bulltrader988
Bulltrader988 Jun. 13 at 7:23 PM
$MIRA next week 👀👀
0 · Reply
Renz27z
Renz27z Jun. 12 at 6:25 PM
$ONDS $BKSY $BNED $MIRA https://music.apple.com/us/album/peach/1460702037?i=1460702045
0 · Reply
Bulltrader988
Bulltrader988 Jun. 9 at 7:12 PM
$MIRA Holding strong... Event next week 👀👀
0 · Reply
FurtherPR1
FurtherPR1 Jun. 6 at 8:39 PM
Great week for $AZ (up 5%) $MIRA (up 3%) $PERF (up 3%) $TELO (up 7%)
0 · Reply
LoveRetailFroth
LoveRetailFroth Jun. 4 at 5:48 PM
$MIRA Come to papa.. Loaded with 75k shares.$5🚀 $VVPR $RXRX $AMLX $ARBE
1 · Reply
Flipdinero101
Flipdinero101 Jun. 3 at 1:48 PM
$MIRA
0 · Reply
Flipdinero101
Flipdinero101 Jun. 3 at 1:47 PM
$MIRA
0 · Reply
anamika_
anamika_ Jun. 3 at 6:12 AM
$MIRA oh dilution coming?
0 · Reply
anamika_
anamika_ Jun. 2 at 1:51 PM
$MIRA easy hold
0 · Reply
Latest News on MIRA
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 28, 2025, 8:30 AM EDT - 19 days ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 8, 2025, 8:00 AM EDT - 5 weeks ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

May 6, 2025, 8:00 AM EDT - 5 weeks ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

Apr 23, 2025, 8:00 AM EDT - 7 weeks ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 16, 2025, 8:00 AM EDT - 2 months ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

Apr 1, 2025, 8:00 AM EDT - 2 months ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Mar 24, 2025, 7:30 AM EDT - 3 months ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

Mar 13, 2025, 8:00 AM EDT - 3 months ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Mar 4, 2025, 8:00 AM EST - 3 months ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 19, 2024, 9:00 AM EST - 6 months ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Dec 10, 2024, 8:30 AM EST - 6 months ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Nov 20, 2024, 7:44 AM EST - 7 months ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Oct 28, 2024, 7:30 AM EDT - 8 months ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

Oct 21, 2024, 7:30 AM EDT - 8 months ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Sep 27, 2024, 7:30 AM EDT - 9 months ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

Sep 18, 2024, 7:00 AM EDT - 9 months ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

Sep 11, 2024, 7:30 AM EDT - 9 months ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

Aug 26, 2024, 8:00 AM EDT - 10 months ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

Aug 19, 2024, 7:30 AM EDT - 10 months ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

Aug 12, 2024, 8:00 AM EDT - 11 months ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

Jul 25, 2024, 7:00 AM EDT - 11 months ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

Jul 22, 2024, 2:33 PM EDT - 11 months ago

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Jul 22, 2024, 8:00 AM EDT - 11 months ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

Jun 24, 2024, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA Announces Positive Test Results

Jun 17, 2024, 2:07 PM EDT - 1 year ago

MIRA Announces Positive Test Results

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

May 29, 2024, 8:45 AM EDT - 1 year ago

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

May 21, 2024, 8:45 AM EDT - 1 year ago

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

May 20, 2024, 8:00 AM EDT - 1 year ago

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

Mar 21, 2024, 11:04 AM EDT - 1 year ago

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

MIRA Pharmaceuticals Provides Corporate Update

Feb 5, 2024, 8:30 AM EST - 1 year ago

MIRA Pharmaceuticals Provides Corporate Update

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

Dec 4, 2023, 8:00 AM EST - 1 year ago

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

Nov 29, 2023, 8:00 AM EST - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time

Nov 21, 2023, 10:42 AM EST - 1 year ago

MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

Nov 21, 2023, 10:09 AM EST - 1 year ago

MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

Nov 20, 2023, 8:00 AM EST - 1 year ago

MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2

MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot

Sep 18, 2023, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot

MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts

Sep 5, 2023, 8:31 AM EDT - 1 year ago

MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts

MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit

Aug 31, 2023, 8:31 AM EDT - 1 year ago

MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit

MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time

Aug 29, 2023, 11:39 AM EDT - 1 year ago

MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time

MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast

Aug 9, 2023, 9:35 AM EDT - 2 years ago

MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast

MIRA Pharmaceuticals to Ring the Nasdaq Opening Bell on Wednesday, August 9, 2023

Aug 9, 2023, 8:47 AM EDT - 2 years ago

MIRA Pharmaceuticals to Ring the Nasdaq Opening Bell on Wednesday, August 9, 2023

MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering

Aug 7, 2023, 4:01 PM EDT - 2 years ago

MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering

MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing

Aug 2, 2023, 6:44 PM EDT - 2 years ago

MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing

Cannabis pharma Mira Pharmaceuticals ups IPO size

Jul 21, 2023, 5:57 PM EDT - 2 years ago

Cannabis pharma Mira Pharmaceuticals ups IPO size

IPO Update: Mira Pharmaceuticals Aims For Mini-IPO

Jul 17, 2023, 5:59 PM EDT - 2 years ago

IPO Update: Mira Pharmaceuticals Aims For Mini-IPO

MIRA Pharmaceuticals Begins U.S. IPO Push

Jun 30, 2023, 1:16 PM EDT - 2 years ago

MIRA Pharmaceuticals Begins U.S. IPO Push

Bulltrader988
Bulltrader988 Jun. 15 at 7:26 PM
$MIRA starts tomorrow 👀👀
0 · Reply
Bulltrader988
Bulltrader988 Jun. 13 at 7:23 PM
$MIRA next week 👀👀
0 · Reply
Renz27z
Renz27z Jun. 12 at 6:25 PM
$ONDS $BKSY $BNED $MIRA https://music.apple.com/us/album/peach/1460702037?i=1460702045
0 · Reply
Bulltrader988
Bulltrader988 Jun. 9 at 7:12 PM
$MIRA Holding strong... Event next week 👀👀
0 · Reply
FurtherPR1
FurtherPR1 Jun. 6 at 8:39 PM
Great week for $AZ (up 5%) $MIRA (up 3%) $PERF (up 3%) $TELO (up 7%)
0 · Reply
LoveRetailFroth
LoveRetailFroth Jun. 4 at 5:48 PM
$MIRA Come to papa.. Loaded with 75k shares.$5🚀 $VVPR $RXRX $AMLX $ARBE
1 · Reply
Flipdinero101
Flipdinero101 Jun. 3 at 1:48 PM
$MIRA
0 · Reply
Flipdinero101
Flipdinero101 Jun. 3 at 1:47 PM
$MIRA
0 · Reply
anamika_
anamika_ Jun. 3 at 6:12 AM
$MIRA oh dilution coming?
0 · Reply
anamika_
anamika_ Jun. 2 at 1:51 PM
$MIRA easy hold
0 · Reply
Hystericgains
Hystericgains May. 30 at 11:16 PM
$MIRA One of these days. Huge green candles
1 · Reply
Bulltrader988
Bulltrader988 May. 28 at 5:19 PM
$MIRA 👀👀
0 · Reply
MrWolf19
MrWolf19 May. 28 at 4:51 PM
$MIRA https://www.zacks.com/stock/research/MIRA/price-target-stock-forecast
0 · Reply
MrWolf19
MrWolf19 May. 28 at 4:47 PM
$MIRA 👀 https://scr.zacks.com/news/news-details/2025/MIRA-Continues-Positive-Testing-Run/default.aspx
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 28 at 1:26 PM
$RXRX Good Morning ☕️ I pay LT taxes in November on all my shares. Perfect timing. $GERN $MIRA $ARBE $VVPR
0 · Reply
Bulltrader988
Bulltrader988 May. 28 at 12:35 PM
$MIRA "... today announced that it will participate in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings planned as it explores potential licensing, strategic partnerships, and M&A opportunities..." 👀👀 https://www.stocktitan.net/news/MIRA/mira-pharmaceuticals-to-participate-in-bio-2025-in-boston-and-e30jf7trpak9.html
0 · Reply
Bulltrader988
Bulltrader988 May. 26 at 7:43 PM
$CMPS $MNMD $CYBN $MIRA 👀👀 https://www.thenew.money/article/washington-has-a-powerful-new-advocate-for-psychedelics
0 · Reply
MrWolf19
MrWolf19 May. 23 at 7:41 AM
$MIRA
0 · Reply
trekker314
trekker314 May. 22 at 4:09 PM
$MIRA Need $SLS to take off before i can buy another 30K shares here
0 · Reply
Bulltrader988
Bulltrader988 May. 22 at 6:31 AM
$MIRA 👀👀 https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-chief-financial-officer?utm_source=webullapp.com&utm_medium=referral
1 · Reply
Bulltrader988
Bulltrader988 May. 22 at 6:26 AM
$MIRA 8k yesterday "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers" 👀👀 https://www.sec.gov/ix?doc=/Archives/edgar/data/1904286/000164117225011936/form8-k.htm
0 · Reply
Flipdinero101
Flipdinero101 May. 21 at 11:20 PM
$MIRA
0 · Reply